Business and Finance Business and Finance
Thu, February 13, 2025
Wed, February 12, 2025

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results


Published on 2025-02-12 16:41:03 - manilatimes
  Print publication without navigation

  • COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.

Ascendis Pharma A/S announced its financial results for the fourth quarter and full year of 2024. The company reported total revenue of $157.6 million for the year, with a significant increase attributed to the sales of SKYTROFA, their once-weekly growth hormone therapy, which generated $145.7 million. Despite this, the company experienced a net loss of $580.7 million for the year, largely due to increased operating expenses, including research and development costs which rose to $378.9 million from $298.6 million the previous year. Operating expenses were driven by higher personnel costs, clinical trial expenses, and manufacturing costs for ongoing and future product launches. Ascendis also highlighted progress in their pipeline, with positive developments in treatments like TransCon PTH for hypoparathyroidism and TransCon CNP for achondroplasia, alongside plans for further regulatory submissions and market expansions.

Read the Full manilatimes Article at:
[ https://www.manilatimes.net/2025/02/13/tmt-newswire/globenewswire/ascendis-pharma-reports-fourth-quarter-and-full-year-2024-financial-results/2054927 ]
Contributing Sources